½ÃÀ庸°í¼­
»óǰÄÚµå
1811983

¼¼°èÀÇ ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ½ÃÀå(2024-2030³â)

Cell Biology Research Market, Global, 2024-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Frost & Sullivan | ÆäÀÌÁö Á¤º¸: ¿µ¹® 51 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

´ÜÀϼ¼Æ÷ ±â¼ú°ú À¯ÀüüÇÐ µµ±¸ÀÇ ¹ßÀüÀ¸·Î ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸´Â Çõ½ÅÀûÀÎ ¼ºÀåÀ» °æÇè

ÀÌ º¸°í¼­´Â ¼¼°è ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ½ÃÀåÀ» Á¶»çÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö ³ôÀº ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, Å« ¼öÀÍÀÇ ÀüȯÁ¡À» ¸ÂÀÌÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº Àåºñ, ¼Ò¸ðǰ, ¼ÒÇÁÆ®¿þ¾î Ç÷§Æû Àü¹Ý¿¡ °ÉÄ£ ±â¼ú Çõ½ÅÀÇ °¡¼ÓÈ­¿Í µ¥ÀÌÅÍ ±â¹Ý ¿¬±¸ ¸ðµ¨, Çаè¿Í ¹ÙÀÌ¿À Á¦¾à»ç °£ÀÇ Çù¾÷ Áõ°¡, ½ÇÇè½Ç ¿öÅ©Ç÷οìÀÇ µðÁöÅÐÈ­¿¡ ÈûÀÔ¾î ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î ¼¼Æ÷ ±â¹Ý Ä¡·á¹ýÀÇ ÃâÇö°ú »ý¹°ÇÐÀû ¿¬±¸ÀÇ º¹À⼺À¸·Î ÀÎÇØ º¸´Ù Á¤±³ÇÑ µµ±¸¿Í ¿öÅ©Ç÷ο찡 ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

ÀÌ ºÐ¼®¿¡´Â ´ÙÀ½ÀÌ Æ÷ÇԵ˴ϴÙ.

  • ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ°í ¾ïÁ¦ÇÏ´Â ¿äÀεé
  • Á¦Ç° À¯Çü(Àåºñ, ¼Ò¸ðǰ ¹× ½Ã¾à, ¼ÒÇÁÆ®¿þ¾î), ÃÖÁ¾ ¿ëµµ(Á¦¾à, Çмú ¹× ¿¬±¸, ÀÓ»ó ½ÇÇè½Ç), ±â¼ú(´ÜÀϼ¼Æ÷ ºÐ¼®, ¶óÀÌºê ¼¿ À̹Ì¡, ÇÏÀ̽º·çDz ½ºÅ©¸®´×, À¯¼¼Æ÷ ºÐ¼®, ¼¼Æ÷¹è¾ç, CRISPR ¹× À¯ÀüÀÚ ÆíÁý, ±âŸ), Áö¿ª(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áß³²¹Ì, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«)º° ¼¼ºÐÈ­
  • °¢ Á¦Ç° ºÎ¹® ¹× ±â¼ú ºÐ¾ßÀÇ ÁÖ¸ñÇÒ ¸¸ÇÑ ±â¾÷

¶ÇÇÑ »ê¾÷ ºÎ¹®, ½ÅÈï ºñÁî´Ï½º ¸ðµ¨, ¼öÀÍ ¹× ¿¹ÃøÀ» Æò°¡ÇÏ¿© ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ºÐ¾ßÀÇ ÁÖ¿ä ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÕ´Ï´Ù.

Á¶»ç±â°£Àº 2024-2030³âÀ¸·Î 2024³âÀ» ±âÁسâ, 2025-2030³âÀ» ¿¹Ãø ±â°£À¸·Î Çϰí ÀÖ½À´Ï´Ù.

¼öÀÍ ¹× ¿¹Ãø

2024³â ¸ÅÃâ¾×Àº 199¾ï 4,000¸¸ ´Þ·¯, 2024-2030³â 7.5%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÐ¼® ¹üÀ§

  • º» ºÐ¼®¿¡¼­´Â ¼¼°è ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ½ÃÀåÀ» Á¶»çÇÕ´Ï´Ù. ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸´Â ½Ã·áÀÇ ¼¼Æ÷¸¦ ºÐ¼®ÇÏ¿© ±× ±¸Á¶, ±â´É, °Åµ¿À» ¿¬±¸ÇÏ´Â °ÍÀÔ´Ï´Ù.
  • ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ½ÃÀå¿¡ ÁÖ¸ñÇÑ ÀÌÀ¯´Â ±â¼úÀÇ ±Þ¼ÓÇÑ ¹ßÀü°ú ¿¬±¸ È¿À²¼º°ú ÀçÇö¼ºÀ» ³ôÀÌ´Â Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.
  • ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸¿¡´Â ¼¼Æ÷¹è¾ç, À̹Ì¡, ´ÜÀϼ¼Æ÷ ºÐ¼®, ¸ÖƼ¿À¹Í½º Á¢±Ù¹ý µî ´Ù¾çÇÑ ±â¼ú°ú ±â¹ýÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ºÐ¾ßÀÇ °³¹ßÀº Áúº´ ±âÀü, Àç»ýÀÇ·á, ¹ÙÀÌ¿ÀÀǾàǰ °³¹ßÀÇ ¹ß°ßÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
  • ¼¼Æ÷»ý¹°ÇÐ ºÐ¾ßÀÇ ÁÖ¿ä Çõ½Å¿¡´Â ÇÏÀ̽º·çDz ½ºÅ©¸®´×(HTS), ÷´Ü À̹Ì¡ ±â¼ú, AI¸¦ Ȱ¿ëÇÑ µ¥ÀÌÅÍ ºÐ¼®ÀÇ ÅëÇÕÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ °³¹ßÀ» ÅëÇØ ¿¬±¸ÀÚµéÀº ¼¼Æ÷ °úÁ¤¿¡ ´ëÇÑ ´õ ±íÀº ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖÀ¸¸ç, ½Å¾à °³¹ß ¹× Ä¡·á Àü·«À» °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ½ÃÀåÀº ¼Ö·ç¼Ç, ¾ÖÇø®ÄÉÀ̼Ç, Á¦Ç° ¹× ¼­ºñ½º Á¦°øÀ¸·Î ºÐ·ùÇÒ ¼ö ÀÖ½À´Ï´Ù. º» Á¶»ç¿¡¼­´Â ¼öÀÍ ÃßÁ¤ ¹× ¿¹Ãø ºÐ¼®À» À§ÇØ ¼¼Æ÷»ý¹°ÇÐ ºÐ¾ßÀÇ ½Å±â¼ú°ú ¿¬±¸ µµ±¸¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.
  • Áö¿ªº° ³»¿ªÀº Á¦Ç° À¯Çüº°·Î¸¸ Ç¥½ÃµÇ¾î ÀÖ½À´Ï´Ù.

¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ¾÷°è¿¡¼­ Àü·«Àû Áß¿ä »çÇ×ÀÇ ¿µÇâ·Â »óÀ§ 3°¡Áö

ÆÄ±«Àû ±â¼ú

  • ´ÜÀϼ¼Æ÷ RNA ½ÃÄö½Ì, CRISPR À¯ÀüÀÚ ÆíÁý, °ø°£ Àü»çüÇÐ, AI¸¦ Ȱ¿ëÇÑ À̹ÌÁö ºÐ¼® µî »õ·Î¿î ±â¼úÀÌ ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸¸¦ À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¼¼Æ÷¿¡ ´ëÇÑ º¸´Ù »ó¼¼ÇÑ ½Ç½Ã°£ ±â´ÉÀû ÀÌÇØ¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© Áúº´ ¸ðµ¨¸µ, Àç»ýÀÇ·á, ½Å¾à°³¹ßÀÇ È¹±âÀûÀÎ ¹ßÀüÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
  • Á¦Á¶¾÷ü¿Í ¿¬±¸ °ø±Þ¾÷üµéÀº ÀÚµ¿È­, ¸ÖƼ¿À¹Í½º ±â´É, ½Ç½Ã°£ ºÐ¼®À» °áÇÕÇÑ È®Àå °¡´ÉÇÏ°í »ç¿ëÇϱ⠽¬¿î µµ±¸¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¼¼Æ÷ ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí, ½Ç¿ëÀûÀÎ Áö½ÄÀ» Á¦°øÇϱâ À§ÇØ ±â±â, ¼ÒÇÁÆ®¿þ¾î, AI ¾Ë°í¸®ÁòÀ» ÅëÇÕÇÑ ½Ã½ºÅÛÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. ½ºÅ¸Æ®¾÷°ú ´ëÇü º¥´õ ¸ðµÎ ÁøÈ­ÇÏ´Â ¿¬±¸ ¿ä±¸¿¡ ´ëÀÀÇϱâ À§ÇØ À¯¿¬¼º, ¸ðµâ¼º, »ç¿ëÀÚ Á¤ÀÇ¿¡ Á¡Á¡ ´õ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù.

º¯ÇõÀû ¸Þ°¡Æ®·»µå

  • °í·ÉÈ­, ¸¸¼ºÁúȯ, »õ·Î¿î Àü¿°º´, ¸ÂÃãÇü ÀÇ·á·ÎÀÇ Àüȯ µî Àü ¼¼°èÀûÀÎ µµÀü°úÁ¦·Î ÀÎÇØ ¼¼Æ÷¿¡ ´ëÇÑ ´õ ±íÀº ÀλçÀÌÆ®ÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀÌ º¸´Ù º¹ÀâÇÑ »ý¸®Àû ¹è°æ¿¡¼­ ¼¼Æ÷ÀÇ °Åµ¿À» ÀÌÇØÇÏ·Á°í ³ë·ÂÇÔ¿¡ µû¶ó, À¯±âü, 3D ¼¼Æ÷¹è¾ç, ÀÏÂ÷ ¼¼Æ÷¿¡ ´ëÇÑ °ü½ÉÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
  • ½ÃÀå °ü°èÀÚµéÀº °øÁߺ¸°Ç ¿ì¼±¼øÀ§¿Í ¼¼°è ¿¬±¸ °úÁ¦¿¡ ¸ÂÃç ¿¬±¸°³¹ß Àü·«À» Á¶Á¤Çϰí ÀÖ½À´Ï´Ù. ±âÃʰúÇаú ÀÓ»ó ÀÀ¿ëÀÇ °¡±³ ¿ªÇÒÀ» ÇÏ´Â Áß°³¿¬±¸ µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸Þ°¡ Æ®·»µå´Â ¼¼Æ÷ ±â¹Ý ºÐ¼® ¹× °íÇÔ·® ½ºÅ©¸®´×(HCS) Ç÷§Æû¿¡ ´ëÇÑ Àå±âÀûÀÎ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

»ê¾÷ À¶ÇÕ

  • ¼¼Æ÷»ý¹°ÇÐÀº µ¥ÀÌÅÍ °úÇÐ, ¹Ì¼¼À¯Ã¼°øÇÐ, Àç·á°úÇÐ, ·Îº¿°øÇÐ µî°ú Á¡Á¡ ´õ ¸¹ÀÌ À¶Çյǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌÁ¾ »ê¾÷ °£ Çù¾÷Àº ÀÚµ¿È­µÈ ¼¿ Çڵ鸵, HTS, °í±Þ ºÐ¼®À» °áÇÕÇÑ Â÷¼¼´ë Ç÷§Æû °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À¶ÇÕÀº ¹ß°ßÀÇ ¼Óµµ¸¦ °¡¼ÓÈ­Çϰí, ¼öÀÛ¾÷¿¡ µû¸¥ ¿À·ù¸¦ ÁÙÀ̸鼭 ¹ß°ßÀÇ ¼Óµµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù.
  • ÁÖ¿ä ±â¾÷µéÀº ÇÏÀÌÅ×Å© ±â¾÷ ¹× Çмú ±â°ü°ú Çù·ÂÇÏ¿© »óÈ£ ¿î¿ë °¡´ÉÇÑ ½º¸¶Æ® ·¦ ¼Ö·ç¼ÇÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ, ¸Ó½Å·¯´×, ½ÇÇè½Ç ÀÚµ¿È­¸¦ ÅëÇÕÇÑ Ç÷§ÆûÀº Ãֽм¼Æ÷»ý¹°ÇÐ ½ÇÇè½Ç¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ÀǾàǰ ¿¬±¸°³¹ß, ÇÕ¼º»ý¹°ÇÐ, Á¤¹ÐÀÇ·á ºÐ¾ß¿¡¼­ »õ·Î¿î ½ÃÀå°ú »ç¿ë»ç·Ê¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä °æÀï»ç

¿µ»ó ±â¼ú

  • Revvity
  • Zeiss Microscopy
  • Nikon Instruments Inc.
  • Leica Microsystems
  • Evident Scientific
  • Bruker Corporation
  • JEOL Ltd.
  • Hitachi High-Tech Corporation
  • PerkinElmer Inc.
  • Molecular Devices LLC
  • GE Healthcare Life Sciences
  • Yokogawa Electric Corporation
  • Amnis Corporation(part of Luminex Corporation)
  • Cytek(R)
  • Chemometec A/S

»çÀÌÅä¸ÞÆ®¸® ±â¼ú

  • BD Biosciences
  • Beckman Coulter(Danaher Corporation)
  • Miltenyi Biotec
  • Sony Biotechnology Inc.
  • Fluidigm Corporation
  • Amnis Corporation(Luminex CorporationÀÇ ÀϺÎ)
  • Nexcleom Bioscience LLC
  • Chemometec A/S

¼¼Æ÷¹è¾ç ±â¼ú

  • Corning Incorporated
  • Greiner Bio-One International GmbH
  • Thermo Fisher Scientific
  • Lonza Group
  • InSphero AG
  • Kuraray Co., Ltd.
  • Sartorius AG
  • Eppendorf AG
  • Appilkon Biotechnology(part of Getinge)
  • Merck KGaA
  • GE Healthcare Life Sciences
  • Cellares
  • CellulaRevolution
  • TissenBioFarm
  • Scinobuh Biotech

¼¼Æ÷ ºÐ¸® ±â¼ú

  • Miltenyi Biotec
  • BD Biosciences
  • Beckman Coulter(Danaher Corporation)
  • Fluidigm Corporation
  • Dolomite Microfluidics

ÃËÁø¿äÀÎ

  • ¿¬±¸ ±â¼ú, ƯÈ÷ CRISPR/Cas9, À¯ÀüÀÚ ÆíÁý, NGSÀÇ ¹ßÀüÀº ¿¬±¸ ´É·Â¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ Á¤¹ÐÇÑ À¯ÀüÀÚ ÆíÁý°ú ½Å¼ÓÇÑ À¯ÀüÀÚ ½ÃÄö½ÌÀ» °¡´ÉÇÏ°Ô ÇÏ¿© À¯ÀüÀÚ Ä¡·á¿Í Á¾¾çÇÐÀÇ Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀ» ÅëÇØ ¿¬±¸ÀÚµéÀº À¯ÀüÀÚ¸¦ Á¤È®ÇÏ°Ô ÆíÁýÇϰí, ¿¬±¸ ¿µ¿ªÀ» È®ÀåÇϰí, Á¾¾çÇÐ, À¯ÀüÇÐ, ¸ÂÃã ÀÇ·á ºÐ¾ßÀÇ ¹ß°ßÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. AI¿Í ÀÚµ¿È­ÀÇ Áö¼ÓÀûÀÎ °³¹ß°ú ÅëÇÕÀ¸·Î ½ÇÇè½Ç ÇÁ·Î¼¼½ºÀÇ È¿À²¼º°ú ÀçÇö¼ºµµ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.
  • ¸ÂÃãÇü Ä¡·á¿Í Àç»ýÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä´Â Áٱ⼼Æ÷ Ä¡·á¿Í À¯ÀüÀÚ º¯Çü ¸é¿ª¼¼Æ÷¸¦ Æ÷ÇÔÇÑ ¼¼Æ÷ ±â¹Ý Ä¡·áÀÇ Á߿伺À» ´õ¿í °­Á¶Çϰí ÀÖ½À´Ï´Ù. ±â¾÷µéÀº Áٱ⼼Æ÷ µî ¼¼Æ÷ Ä¡·á ¼Ö·ç¼Ç °³¹ß¿¡ ÁýÁßÇϰí ÀÖÀ¸¸ç, ¾ËÃ÷ÇÏÀ̸Ó, ´ç´¢º´, ½ÉÀ庴 µîÀÇ Áúº´À» Ä¡·áÇÏ´Â Àç»ýÀÇ·á¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù.
  • ¾Ï, ´ç´¢º´, ½ÉÇ÷°üÁúȯÀ» Æ÷ÇÔÇÑ ¸¸¼ºÁúȯÀÌ Àü ¼¼°èÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó º¸´Ù Áøº¸µÈ ¿¬±¸ µµ±¸¿Í ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¶§¹®¿¡ Àç»ýÀǷᳪ À¯ÀüÀÚ Ä¡·á¿Í °°Àº ºÐ¾ß¿¡¼­´Â ÀÌ·¯ÇÑ Áúº´À» º¸´Ù È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§ÇÑ ¸ÂÃãÇü Ä¡·á ¿É¼Ç¿¡ ÃÊÁ¡À» ¸ÂÃá ÀÚ±Ý Áö¿ø°ú ±â¼ú Çõ½ÅÀÌ È°¹ßÈ÷ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù.
  • Çмú±â°ü, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, Á¦¾à±â¾÷ °£ÀÇ Àü·«Àû ÆÄÆ®³Ê½ÊÀº ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀÎÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Çù·Â °ü°è´Â Àü¹® Áö½Ä, ÀÚ¿ø ¹× ÀÚ±ÝÀ» °øÀ¯ÇÏ¿© ±â¼ú Çõ½ÅÀÇ ¼Óµµ¸¦ °¡¼ÓÈ­ÇÏ°í »õ·Î¿î Ä¡·á¹ý°ú ¿¬±¸ µµ±¸ÀÇ °³¹ßÀ» ÃËÁøÇÕ´Ï´Ù.
  • ƯÈ÷ À¯ÀüÀÚ ÆíÁý°ú Áٱ⼼Æ÷ Ä¡·á¿¡ ´ëÇÑ ±ÔÁ¦ »óȲÀÇ ÁøÈ­°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ, ÀÓ»ó½ÃÇè, Á¦Ç° ½ÂÀο¡ ´ëÇÑ Á¤ºÎ ¹× ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀÌ °­È­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â ¿¬±¸¿Í »ó¿ëÈ­¿¡ µµ¿òÀÌ µÇ´Â ±ÔÁ¦ ȯ°æÀÌ Á¶¼ºµÇ°í ÀÖÀ½À» ½Ã»çÇϸç, ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ºÐ¾ßÀÇ Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¼ºÀå ¾ïÁ¦¿äÀÎ

  • À¯ÀüÀÚ ÆíÁý Ç÷§Æû, ÇÏÀ̽º·çDz ½ÃÄö½Ì ½Ã½ºÅÛ µî ÷´Ü ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ µµ±¸ ¹× ±â¼úÀÇ ¿¬±¸°³¹ß ºñ¿ëÀÌ ¿©ÀüÈ÷ ³ôÀº °ÍÀÌ Å« À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸±â°ü°ú »ý¸í°øÇÐ ±â¾÷µéÀº ³ôÀº Ãʱâ ÅõÀÚºñ¿ëÀ¸·Î ÀÎÇØ ±â¼ú Çõ½ÅÀÇ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¹»êÀÌ ÇÑÁ¤µÈ ¼Ò±Ô¸ð Á¶Á÷À̳ª ¿¬±¸¼ÒÀÇ °æ¿ì, ÀÌ·¯ÇÑ ±â¼úÀ» Àú·ÅÇÏ°Ô ±¸ÀÔÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù.
  • CRISPR/Cas9, NGS, PCR µî ÷´Ü ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ±â¼úÀ» ´Ù·ê ¼ö ÀÖ´Â ¼÷·ÃµÈ Àü¹®°¡°¡ Àü ¼¼°èÀûÀ¸·Î ºÎÁ·ÇÕ´Ï´Ù. À¯´ÉÇÑ ÀÎÀç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇÑ Àü¹® ±³À° ¹× ÈÆ·Ã ÇÁ·Î±×·¥Àº ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÃæºÐÇÑ ±³À°À» ¹ÞÀº ÀηÂÀÌ ¾ø´Ù¸é, ÀÌ·¯ÇÑ ±â¼úÀÇ µµÀÔ°ú È¿°úÀûÀΠȰ¿ëÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ±â¼úÀÇ ±Þ¼ÓÇÑ ¹ßÀü¿¡µµ ºÒ±¸Çϰí Á¤È®¼º, ÀçÇö¼º, È®À强 Ãø¸é¿¡¼­ µµ±¸ÀÇ º¹À⼺°ú ±â¼úÀû ÇѰè´Â ¿©ÀüÈ÷ Á¸ÀçÇÕ´Ï´Ù. NGS¿¡¼­ ¾òÀº µ¥ÀÌÅÍÀÇ ÇØ¼®°ú À¯ÀüÀÚ ÆíÁýÀÇ È¿À²¼º¿¡ ´ëÇÑ ¹®Á¦µµ ¿©ÀüÈ÷ ÇØ°áÇØ¾ß ÇÒ °úÁ¦ÀÔ´Ï´Ù.
  • ȯÀÚÀÇ À¯ÀüÀÚ µ¥ÀÌÅÍ¿Í ¹Î°¨ÇÑ »ý¹°ÇÐÀû Á¤º¸¸¦ »ç¿ëÇÏ´Â ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹× º¸¾È¿¡ ´ëÇÑ ¿ì·Á°¡ Ä¿Áö°í ÀÖ½À´Ï´Ù. GDPR°ú °°Àº µ¥ÀÌÅÍ º¸È£ ±ÔÁ¦ÀÇ °­È­´Â ´ë±Ô¸ð µ¥ÀÌÅͼ¼Æ®¸¦ °ü¸®ÇÏ´Â ±â¾÷ ¹× ¿¬±¸±â°ü¿¡ µµÀü°úÁ¦¸¦ ´øÁ®ÁÖ°í ÀÖ½À´Ï´Ù. º¸¾È Ä§ÇØ°¡ ¹ß»ýÇÏ¸é ±â¼ú¿¡ ´ëÇÑ ½Å·Ú°¡ ¶³¾îÁö°í ½ÃÀå ¼ºÀåÀÌ µÐÈ­µÉ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¶»ç ¹üÀ§

¼ºÀå ȯ°æ : ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ½ÃÀåÀÇ º¯È­

  • ¼ºÀåÀÌ Á¡Á¡ ´õ ¾î·Á¿öÁö´Â ÀÌÀ¯
  • Àü·«Àû °úÁ¦
  • ¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ »ê¾÷¿¡¼­ ¼¼ °¡Áö Àü·«Àû °úÁ¦°¡ ¹ÌÄ¡´Â ¿µÇâ

¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ½ÃÀåÀÇ »ýŰè

  • °æÀï ȯ°æ
  • ÁÖ¿ä °æÀï»ç

¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀÎ

  • ¼ºÀå ÁöÇ¥
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ¿¹Ãø °í·Á»çÇ×
  • ¼öÀÍ ¿¹Ãø
  • Á¦Ç°º° ¼öÀÍ ¿¹Ãø
  • ÃÖÁ¾»ç¿ëÀÚº° ¼öÀÍ ¿¹Ãø
  • ±â¼úº° ¼öÀÍ ¿¹Ãø
  • Áö¿ªº° ¼öÀÍ ¿¹Ãø
  • ¼öÀÍ ¿¹Ãø ºÐ¼®
  • Á¦Ç°º° ¼öÀÍ ¿¹Ãø ºÐ¼®
  • ÃÖÁ¾»ç¿ëÀÚº° ¼öÀÍ ¿¹Ãø ºÐ¼®
  • ±â¼úº° ¼öÀÍ ¿¹Ãø ºÐ¼®
  • Áö¿ªº° ¼öÀÍ ¿¹Ãø ºÐ¼®
  • °¡°Ý µ¿Çâ ¹× ¿¹Ãø ºÐ¼®
  • ¼öÀÍ ¹èºÐ
  • ±â¾÷ ¸ÅÆ®¸¯½º
  • ±â¾÷ Æ÷Æ®Æú¸®¿À
  • ¼öÀÍ ºÐ¹è ºÐ¼®

ÁÖ¸ñ¹Þ´Â ±â¾÷ : ´ÜÀϼ¼Æ÷ ºÐ¼®

  • ÁÖ¸ñ¹Þ´Â ±â¾÷ : »ý¼¼Æ÷ À̹Ì¡
  • ÁÖ¸ñ¹Þ´Â ±â¾÷ : ÇÏÀ̽º·çDz ½ºÅ©¸®´×
  • ÁÖ¸ñ¹Þ´Â ±â¾÷ : À¯¼¼Æ÷ ºÐ¼®
  • ÁÖ¸ñ¹Þ´Â ±â¾÷ : ¼¼Æ÷¹è¾ç
  • ÁÖ¸ñ¹Þ´Â ±â¾÷ : CRISPR°ú À¯ÀüÀÚ ÆíÁý
  • ÁÖ¸ñ ±â¾÷ : ±âŸ

¼ºÀå ÃËÁø¿äÀÎ : Àåºñ

  • ¼ºÀå ÁöÇ¥
  • ¼öÀÍ ¿¹Ãø
  • Áö¿ªº° ¼öÀÍ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®

¼ºÀå ÃËÁø¿äÀÎ : ¼Ò¸ðǰ ¹× ½Ã¾à

  • ¼ºÀå ÁöÇ¥
  • ¼öÀÍ ¿¹Ãø
  • Áö¿ªº° ¼öÀÍ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®

¼ºÀå ÃËÁø¿äÀÎ : ¼ÒÇÁÆ®¿þ¾î

  • ¼ºÀå ÁöÇ¥
  • ¼öÀÍ ¿¹Ãø
  • Áö¿ªº° ¼öÀÍ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®

¼¼Æ÷»ý¹°ÇÐ ¿¬±¸ ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ

  • ¼ºÀå ±âȸ 1 : ¿öÅ©Ç÷οì ÅëÇÕÀ» À§ÇÑ ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼Ç Á¦ÀÛ
  • ¼ºÀå ±âȸ 2 : ´ÜÀϼ¼Æ÷ ºÐ¼®°ú À¯ÀüüÇÐ ¹× À¯ÀüÀÚ ÆíÁý µµ±¸ÀÇ °áÇÕ
  • ¼ºÀå ±âȸ 3 : ¹ÙÀÌ¿ÀÀǾàǰ ¹× Áß°³¿¬±¸¸¦ À§ÇÑ ¸ÂÃãÇü ¼Ö·ç¼Ç °³¹ß

ºÎ·Ï ¹× ´ÙÀ½ ´Ü°è

KSM 25.09.24

Cell Biology Research is Experiencing Transformational Growth due to Advances in Single-Cell Technologies and Genomics Tools

In the study, Frost & Sullivan examines the global cell biology research market. The market is projected to register high growth between 2024 and 2030, reaching significant revenue milestones. This growth reflects accelerating innovation across instrumentation, consumables, and software platforms, with a firm push from data-driven research models, increased academic and biopharma collaboration, and the digitalization of lab workflows. In addition, the emergence of new cell-based therapies and the increasing complexity of biological research call for more sophisticated tools and workflows.

This analysis includes:

  • Factors driving and restraining the adoption of cell biology research solutions
  • Segmentation by product type (instruments, consumables and reagents, software), end use (pharma, academia and research, clinical labs), technology (single-cell analysis, live-cell imaging, high-throughput screening, flow cytometry, cell culture, CRISPR and gene editing, others), and region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa)
  • Notable companies in each product segment and technology

Frost & Sullivan also identifies the major growth opportunities in the cell biology research space by evaluating the industry segments, emerging business models, and revenues and forecasts.

The study period is 2024-2030, with 2024 as the base year and 2025-2030 as the forecast period.

Revenue Forecast

The revenue estimate for the base year 2024 is $19.94 billion, with a CAGR of 7.5% for the study period 2024-2030.

Scope of Analysis

  • This analysis examines the global cell biology research market, which involves analyzing cells from a sample to study their structure, function, and behavior.
  • Frost & Sullivan has focused on the cell biology research market due to its rapid advancements in technology and increasing demand for innovative solutions that enhance research efficiency and reproducibility.
  • Cell biology research encompasses a wide range of techniques and technologies, including cell culture, imaging, single-cell analysis, and multomics approaches. Advances in these areas are driving discoveries in disease mechanisms, regenerative medicine, and biopharmaceutical development.
  • Key innovations in cell biology include the integration of high-throughput screening (HTS), advanced imaging techniques, and AI-driven data analysis. These developments enable researchers to gain deeper insights into cellular processes, improving drug discovery and therapeutic strategies.
  • The market can be categorized into solutions, applications, and product and service offerings. This study focuses on emerging technologies and research tools within cell biology for revenue estimation and forecast analysis.
  • The regional breakdown is only provided for the product type segment.

The Impact of the Top 3 Strategic Imperatives on the Cell Biology Research Industry

Disruptive Technologies

  • Why: Emerging technologies such as single-cell RNA sequencing, CRISPR gene editing, spatial transcriptomics, and AI-powered image analysis are reshaping cell biology research. These innovations enable a more detailed, real-time, and functional understanding of cells, supporting breakthroughs in disease modeling, regenerative medicine, and drug discovery.
  • Frost Perspective: Manufacturers and research suppliers are investing in scalable, user-friendly tools that combine automation, multiomics capabilities, and real-time analytics. There is growing emphasis on systems that integrate instruments, software, and AI algorithms to streamline cellular workflows and deliver actionable insights. Start-ups and larger vendors alike increasingly focus on flexibility, modularity, and customization to meet evolving research needs.

Transformative Megatrends

  • Why: Global challenges, including an aging population, chronic disease burden, emerging pandemics, and the shift toward personalized medicine, are driving demand for deeper cellular insights. As researchers seek to understand cell behavior in more complex physiological contexts, interest in organoids, 3D cell cultures, and primary cells has surged.
  • Frost Perspective: Market players are aligning their R&D strategies with public health priorities and global research agendas. The demand for translational research tools that bridge basic science and clinical application is growing fast. These megatrends are fueling long-term investment in cell-based assays and high-content screening (HCS) platforms.

Industry Convergence

  • Why: Cell biology increasingly intersects with data science, microfluidics, materials science, and robotics. These cross-industry collaborations are driving the development of next-gen platforms that combine automated cell handling, HTS, and advanced analytics. This convergence is accelerating the pace of discovery while reducing variability and manual errors.
  • Frost Perspective: Leading vendors are partnering with tech companies and academic institutions to develop interoperable, smart lab solutions. Platforms that integrate cloud computing, machine learning, and lab automation are becoming essential for modern cell biology labs. This is opening new markets and use cases, particularly in pharma R&D, synthetic biology, and precision medicine.

Key Competitors

Imaging Technologies

  • Revvity
  • Zeiss Microscopy
  • Nikon Instruments Inc.
  • Leica Microsystems
  • Evident Scientific
  • Bruker Corporation
  • JEOL Ltd.
  • Hitachi High-Tech Corporation
  • PerkinElmer Inc.
  • Molecular Devices LLC
  • GE Healthcare Life Sciences
  • Yokogawa Electric Corporation
  • Amnis Corporation (part of Luminex Corporation)
  • Cytek(R)
  • Chemometec A/S

Cytometric Technologies

  • BD Biosciences
  • Beckman Coulter (Danaher Corporation)
  • Miltenyi Biotec
  • Sony Biotechnology Inc.
  • Fluidigm Corporation
  • Amnis Corporation (part of Luminex Corporation)
  • Nexcleom Bioscience LLC
  • Chemometec A/S

Cell Culture Technologies

  • Corning Incorporated
  • Greiner Bio-One International GmbH
  • Thermo Fisher Scientific
  • Lonza Group
  • InSphero AG
  • Kuraray Co., Ltd.
  • Sartorius AG
  • Eppendorf AG
  • Appilkon Biotechnology (part of Getinge)
  • Merck KGaA
  • GE Healthcare Life Sciences
  • Cellares
  • CellulaRevolution
  • TissenBioFarm
  • Scinobuh Biotech

Cell Separation Technologies

  • Miltenyi Biotec
  • BD Biosciences
  • Beckman Coulter (Danaher Corporation)
  • Fluidigm Corporation
  • Dolomite Microfluidics

Growth Drivers

  • Advances in research technologies, particularly in CRISPR/Cas9, gene editing, and NGS, are revolutionizing research capabilities, enabling precision gene editing and rapid genetic sequencing, and driving innovation in gene therapy and oncology. These technologies allow researchers to edit genes precisely, expand study areas, and accelerate discoveries in oncology, genetics, and personalized medicine. The continued development and integration of AI and automation are also improving efficiency and reproducibility in lab processes.
  • Demand for personalized therapies and regenerative medicine is leading to greater emphasis on cell-based therapies, including stem cell therapies and gene-modified immune cells. Companies are focusing on the development of cell therapy solutions, such as stem cells, which are becoming pivotal in regenerative medicine in treating diseases like Alzheimer's, diabetes, and heart disease.
  • The global rise in chronic diseases, including cancer, diabetes, and cardiovascular diseases, is driving demand for more advanced research tools and solutions. This has led to increased funding and innovation in fields like regenerative medicine and gene therapy, with a focus on personalized treatment options to manage these conditions more effectively.
  • Strategic partnerships between academic institutions, biotech firms, and pharmaceutical companies are key drivers of growth in the Cell Biology Research Market. These collaborations enable the pooling of expertise, resources, and funding, accelerating the pace of innovation and facilitating the development of new therapies and research tools.
  • The evolving regulatory landscape, particularly for gene editing and stem cell therapies, is facilitating market growth. Government and regulatory bodies' support for biotechnology, clinical trials, and product approvals is strengthening. This signals a regulatory environment conducive to research and commercialization and encourages innovation in the field of cell biology research.

Growth Restraints

  • The high R&D cost of advanced cell biology research tools and technologies, such as gene editing platforms and high-throughput sequencing systems, remains a significant barrier. Research institutions and biotech companies face high initial investments, which can slow down innovation. It also hinders the affordability of these technologies for smaller organizations or labs with limited budgets.
  • There is a global shortage of skilled professionals capable of working with advanced cell biology research technologies, such as CRISPR/Cas9, NGS, and PCR. Specialized training and education programs to meet the increasing demand for qualified personnel are critical. Without an adequately trained workforce, the adoption and effective use of these technologies can be hindered.
  • Complexity and technical limitations of tools in terms of precision, reproducibility, and scalability still occur despite rapid technological advancements. Challenges in data interpretation from NGS or the efficiency of gene editing still need to be addressed.
  • Concerns regarding data privacy and security have become more prominent as more cell biology research is conducted using patient genetic data and sensitive biological information. Stricter data protection regulations, such as GDPR, pose challenges for companies and research institutions managing large datasets. Any breaches in security could undermine trust in the technologies and slow market growth.

Table of Contents

Research Scope

  • Scope of Analysis
  • Segmentation

Growth Environment: Transformation in the Cell Biology Research Market

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8
  • The Impact of the Top 3 Strategic Imperatives on the Cell Biology Research Industry

Ecosystem in the Cell Biology Research Market

  • Competitive Environment
  • Key Competitors

Growth Generator in the Cell Biology Research Market

  • Growth Metrics
  • Growth Drivers
  • Growth Restraints
  • Forecast Considerations
  • Revenue Forecast
  • Revenue Forecast by Product
  • Revenue Forecast by End User
  • Revenue Forecast by Technology
  • Revenue Forecast by Region
  • Revenue Forecast Analysis
  • Revenue Forecast Analysis by Product
  • Revenue Forecast Analysis by End User
  • Revenue Forecast Analysis by Technology
  • Revenue Forecast Analysis by Region
  • Pricing Trends and Forecast Analysis
  • Revenue Share
  • Company Matrix
  • Company Portfolio
  • Revenue Share Analysis

Companies to Watch: Single-Cell Analysis

  • Companies to Watch: Live-Cell Imaging
  • Companies to Watch: High-Throughput Screening
  • Companies to Watch: Flow Cytometry
  • Companies to Watch: Cell Culture
  • Companies to Watch: CRISPR and Gene Editing
  • Companies to Watch: Others*

Growth Generator: Instruments

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Region
  • Forecast Analysis

Growth Generator: Consumables and Reagents

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Region
  • Forecast Analysis

Growth Generator: Software

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Region
  • Forecast Analysis

Growth Opportunity Universe in the Cell Biology Research Market

  • Growth Opportunity 1: Create Software Solutions for Workflow Integration
  • Growth Opportunity 2: Combine Single-Cell Analysis with Genomics and Gene Editing Tools
  • Growth Opportunity 3: Develop Custom Solutions for Biopharma and Translational Research

Appendix & Next Steps

  • Benefits and Impacts of Growth Opportunities
  • Next Steps
  • List of Exhibits
  • Legal Disclaimer
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦